Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (6): 553-556.doi: 10.35541/cjd.20190922
• Reviews • Previous Articles
Liang Gaopeng, Song Zhiqiang
Received:
2019-09-23
Revised:
2020-05-22
Online:
2021-06-15
Published:
2021-05-31
Contact:
Song Zhiqiang
E-mail:drsongzq@hotmail.com
Supported by:
Liang Gaopeng, Song Zhiqiang. Role of immunoglobulin E autoantibodies in autoimmune skin diseases[J]. Chinese Journal of Dermatology, 2021, 54(6): 553-556.doi:10.35541/cjd.20190922
[1] | Sanjuan MA, Sagar D, Kolbeck R. Role of IgE in autoimmunity[J]. J Allergy Clin Immunol, 2016,137(6):1651⁃1661. doi: 10. 1016/j.jaci.2016.04.007. |
[2] | Lin K, Xu W, Li W, et al. Establishment of a novel quantum dots⁃encoded microbead⁃based flow cytometric method for quantification of soluble FcεRIα in serum[J]. Cytometry A, 2017,91(7):686⁃693. doi: 10.1002/cyto.a.23128. |
[3] | Dema B, Pellefigues C, Hasni S, et al. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis[J/OL]. PLoS One, 2014,9(2):e90424. doi: 10.1371/journal.pone.0090424. |
[4] | Henault J, Riggs JM, Karnell JL, et al. Self⁃reactive IgE exacerbates interferon responses associated with autoimmunity[J]. Nat Immunol, 2016,17(2):196⁃203. doi: 10.1038/ni.3326. |
[5] | Brilland B, Scherlinger M, Khoryati L, et al. Platelets and IgE: shaping the innate immune response in systemic lupus erythematosus[J]. Clin Rev Allergy Immunol, 2020,58(2):194⁃212. doi: 10.1007/s12016⁃019⁃08744⁃x. |
[6] | Kamata A, Kurihara Y, Funakoshi T, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results[J]. Br J Dermatol, 2020,182(5):1221⁃1227. doi: 10.1111/bjd.18364. |
[7] | van Beek N, Schulze FS, Zillikens D, et al. IgE⁃mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases[J]. Expert Rev Clin Immunol, 2016,12(3):267⁃277. doi: 10.1586/1744666X.2016.1123092. |
[8] | Ujiie H. IgE autoantibodies in bullous pemphigoid[J]. Br J Dermatol, 2017,177(6):1481⁃1482. doi: 10.1111/bjd.16034. |
[9] | van Beek N, Lüttmann N, Huebner F, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity[J]. JAMA Dermatol, 2017,153(1):30⁃38. doi: 10.1001/jamadermatol.2016.3357. |
[10] | Schmetzer O, Lakin E, Topal FA, et al. IL⁃24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2018,142(3):876⁃882. doi: 10.1016/j.jaci.2017.10.035. |
[11] | Hatada Y, Kashiwakura J, Hayama K, et al. Significantly high levels of anti⁃dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients[J]. Int Arch Allergy Immunol, 2013,161 Suppl 2:154⁃158. doi: 10.1159/000350388. |
[12] | Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review[J]. Allergy, 2017,72(10):1440⁃1460. doi: 10. 1111/all.13182. |
[13] | Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies[J]. Allergol Int, 2017,66(3):398⁃403. doi: 10.1016/j.alit.2016.12.002. |
[14] | Augusto JF, Truchetet ME, Charles N, et al. IgE in lupus pathogenesis: friends or foes?[J]. Autoimmun Rev, 2018,17(4):361⁃365. doi: 10.1016/j.autrev.2017.11.027. |
[15] | Miyamoto D, Santi CG, Aoki V, et al. Bullous pemphigoid[J]. An Bras Dermatol, 2019,94(2):133⁃146. doi: 10.1590/abd1806⁃4841.20199007. |
[16] | Schmidt E, Zillikens D. Pemphigoid diseases[J]. Lancet, 2013,381(9863):320⁃332. doi: 10.1016/S0140⁃6736(12)61140⁃4. |
[17] | Maurer M, Metz M, Magerl M, et al. Autoreactive urticaria and autoimmune urticaria[J]. Hautarzt, 2004,55(4):350⁃356. doi: 10.1007/s00105⁃004⁃0692⁃9. |
[18] | Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345. |
[19] | Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real⁃life clinical practice[J]. Drug Des Devel Ther, 2019,13:3181⁃3186. doi: 10.2147/DDDT.S214307. |
[20] | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
[21] | Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature[J]. Pharmacotherapy, 2017,37(4):464⁃480. doi: 10.1002/phar.1915. |
[22] | Navinés⁃Ferrer A, Serrano⁃Candelas E, Molina⁃Molina GJ, et al. IgE⁃related chronic diseases and anti⁃IgE⁃based treatments[J]. J Immunol Res, 2016,2016:8163803. doi: 10.1155/2016/8163803. |
[23] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[24] | Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin[J]. Theranostics, 2017,7(5):1266⁃1276. doi: 10.7150/thno.18304. |
[25] | Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria[J]. Ann Allergy Asthma Immunol, 2020,124(1):2⁃12. doi: 10.1016/j.anai.2019.08.014. |
[26] | Hasni S, Gupta S, Davis M, et al. Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti⁃IgE monoclonal antibody in systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019,71(7):1135⁃1140. doi: 10.1002/art. 40828. |
[27] | Seyed Jafari SM, Gadaldi K, Feldmeyer L, et al. Effects of Omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid[J]. Front Immunol, 2019,10:1919. doi: 10.3389/fimmu.2019.01919. |
[28] | Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature[J]. Int J Dermatol, 2017,56(1):18⁃26. doi: 10.1111/ijd.13353. |
[29] | Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial[J]. JAMA Pediatr, 2019,174(1):29⁃37. doi: 10. 1001/jamapediatrics.2019.4476. |
[30] | El⁃Qutob D. Off⁃label uses of omalizumab[J]. Clin Rev Allergy Immunol, 2016,50(1):84⁃96. doi: 10.1007/s12016⁃015⁃8490⁃y. |
[1] | Committee on Autoimmune Diseases, China Dermatologist Association. Azathioprine in the treatment of immune?related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2021, 54(2): 116-121. |
[2] | Zhao Zuotao. Diagnosis and treatment of chronic urticaria: current status and future prospects [J]. Chinese Journal of Dermatology, 2021, 54(12): 1105-1109. |
[3] | Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab) [J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062. |
[4] | Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2021, 0(1): 20200162-e20200162. |
[5] | Liu Wan, Wu Yatong, Gao Xiaoman, Yang Min, Bao Yingqiu, Fu Yu, Chang Jianmin. Analysis of factors associated with skin lesion distribution in 1 125 patients with non-segmental vitiligo [J]. Chinese Journal of Dermatology, 2020, 53(3): 214-219. |
[6] | Chen Wenjuan, Peng Chen, Ding Yangfeng, Shi Yuling. Psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2020, 53(2): 147-151. |
[7] | Committee on Autoimmune Diseases, China Dermatologist Association. Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2020, 53(11): 869-874. |
[8] | Chen Yudi, Geng Peng, Zhao Jiahui, Tu Ping, Zhao Zuotao. Chronic spontaneous urticaria: therapeutic mechanism of omalizumab and assessment of its clinical efficacy [J]. Chinese Journal of Dermatology, 2019, 52(9): 652-655. |
[9] | Zhang Yu, Han Yue, Xu Beilei, Ling Shiqi, Luo Yang, Liu Xiaochun, Yao Xu. Establishment of a mouse model of atopic dermatitis induced by topical application of ovalbumin and calcipotriol [J]. Chinese Journal of Dermatology, 2019, 52(7): 481-485. |
[10] | Chen Anwei, Bai Xiaoming, Wang Hua. Mas-related G protein-coupled receptor X2: a novel receptor for non-IgE-dependent activation of mast cells [J]. Chinese Journal of Dermatology, 2019, 52(2): 142-144. |
[11] | Pediatric Dermatology Committee, China Dermatologist Association, Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association. Expert consensus on diagnosis and management of food allergy in children with atopic dermatitis [J]. Chinese Journal of Dermatology, 2019, 52(10): 711-716. |
[12] | Zheng Lin, Shi Zhenrui, He Mintong, Tan Guozhen. Omalizumab for the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2019, 52(1): 60-63. |
[13] | . Excessive selenium supplementation aggravates atopic dermatitis-like skin lesions induced by dinitrochlorobenzene in mice [J]. Chinese Journal of Dermatology, 2018, 51(7): 495-499. |
[14] | Li Yuanjun, Zhang Xinglian, Zhang Huanzhen, Zhang Xianhui, Liu Runtao, Wang Hui, Han Yuyang, Li Junna, Liu Qiang. Association analysis between the serum level of vitamin D and severity of atopic dermatitis in infants [J]. Chinese Journal of Dermatology, 2017, 50(11): 825-828. |
[15] | . Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: 126 case report [J]. Chinese Journal of Dermatology, 2011, 44(5): 370-370. |
|